Antithrombotic effects of tetramethylpyrazine in in vivo experiments

被引:17
作者
Sheu, JR
Hsiao, G
Lee, YM
Yen, MH
机构
[1] Taipei Med Univ, Grad Inst Med Sci, Taipei 110, Taiwan
[2] Taipei Med Univ, Dept Pharmacol, Taipei 110, Taiwan
[3] Natl Def Med Ctr, Dept Pharmacol, Taipei, Taiwan
关键词
tetramethylpyrazine; fluorescein sodium; occlusion time; platelet plug formation; arterial thrombosis;
D O I
10.1007/BF02981969
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this study, tetramethylpyrazine (TMPZ) was effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at doses of 40 and 80 mug/g. In addition, intravenous injection of TMPZ (10 mug/g) significantly prolonged the bleeding time by approximately 1.5-fold compared with normal saline in severed mesenteric arteries of rats. Continuous infusion of TMPZ (1 mug/g per min) for 10 minutes also significantly increased the bleeding time approximately 1.6-fold, and the bleeding time returned to baseline within 60 minutes after cessation of TMPZ infusion. On the other hand. platelet thrombi formation was induced by irradiation of mesenteric venules with filtered light in mice pretreated intravenously with fluorescein sodium (10 mug/kg). When it was intravenously injected, TMPZ (250 mug/g) significantly prolonged the latent period of the induction of platelet plug formation in mesenteric venules. TMPZ (250 mug/g) prolonged occlusion time approximately 1.4-fold (183 +/- 18 seconds) compared with that of normal saline (132 +/- 14 seconds). Furthermore. aspirin (300 mug/g) showed similar activity in the prolongation of occlusion time in this experiment. In conclusion, these results suggest that TMPZ has effective antithrombotic activity in vivo and may be a potential therapeutic agent for arterial thrombosis but must be assessed further for toxicity. (C) 2001 The Japanese Society of Hematology.
引用
收藏
页码:393 / 398
页数:6
相关论文
共 23 条
[1]  
*BEIJ I PHARM IND, 1977, CHIN MED J, V4, P319
[2]  
Beijing Institute of Pharmaceutical Industry, 1977, CHIN MED J, V7, P420
[3]  
Beijing Institute of Pharmaceutical Industry, 1977, CHIN MED J, V8, P467
[4]  
CALLAHAN A. B., 1960, ANGIOLOGY, V11, P35, DOI 10.1177/000331976001100107
[5]  
CHEN KJ, 1992, CHINESE MED J-PEKING, V105, P870
[6]   CORONARY AND SYSTEMIC HEMODYNAMIC-EFFECTS OF TETRAMETHYLPYRAZINE IN THE DOG [J].
DAI, XZ ;
BACHE, RJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1985, 7 (05) :841-849
[7]   THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE [J].
GENT, M ;
EASTON, JD ;
HACHINSKI, VC ;
PANAK, E ;
SICURELLA, J ;
BLAKELY, JA ;
ELLIS, DJ ;
HARBISON, JW ;
ROBERTS, RS ;
TURPIE, AGG .
LANCET, 1989, 1 (8649) :1215-1220
[8]   A RANDOMIZED TRIAL COMPARING TICLOPIDINE HYDROCHLORIDE WITH ASPIRIN FOR THE PREVENTION OF STROKE IN HIGH-RISK PATIENTS [J].
HASS, WK ;
EASTON, JD ;
ADAMS, HP ;
PRYSEPHILLIPS, W ;
MOLONY, BA ;
ANDERSON, S ;
KAMM, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (08) :501-507
[9]   TETRAMETHYLPYRAZINE FOR TREATMENT OF EXPERIMENTALLY INDUCED STROKE IN MONGOLIAN GERBILS [J].
HO, WKK ;
WEN, HL ;
LEE, CM .
STROKE, 1989, 20 (01) :96-99
[10]  
LU CS, 1978, CHINESE MED J-PEKING, V4, P43